Randomized, open-label comparison of epoetin alfa extended dosing (80,000 U every two weeks) versus weekly dosing (40,000 U weekly) in anemic patients with cancer receiving chemotherapy

Journal of Supportive Oncology

Volumn 5, Issue 4 SUPPL. 2, 2007, Pages 16-17

  Henry, David H ^a   Williams, Denise ^a   Xie, John ^a   Wilhelm, Francois ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; BLOOD TRANSFUSION; BREAST CANCER; CANCER; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KAPLAN MEIER METHOD; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 34250674074     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (1)

1. Henry DH, Kamin M, Wilhelm F, Williams D, Xie J, Woodman RC. Final results of a randomized study comparing two dosing regimens of epoetin alfa in patients with chemotherapy-induced anemia: 80,000 U every two weeks vs 40,000 U weekly. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, Georgia. Abstract 8624.